The Deadly Reality of Pancreatic Cancer

Pancreatic cancer remains one of the most formidable challenges in oncology, characterized by its aggressive nature and poor prognosis. Pancreatic ductal adenocarcinoma (PDAC), which accounts for over 90 percent of all pancreatic cancer cases, is particularly notorious. In 2026, the American Cancer Society projects approximately 67,530 new diagnoses and 52,740 deaths from pancreatic cancer in the United States alone. The five-year relative survival rate hovers around 13 percent overall, with stark variations by stage: 44 percent for localized disease, 17 percent for regional spread, and a mere 3 percent for distant metastases. These figures underscore the urgent need for breakthroughs in understanding tumor biology and overcoming treatment barriers.

Current standard treatments include surgery for the few eligible patients, radiation, and chemotherapy regimens led by gemcitabine, a nucleoside analog that disrupts DNA synthesis in rapidly dividing cancer cells. However, resistance to gemcitabine develops rapidly, limiting its efficacy and contributing to the dismal outcomes.

Non-Coding RNAs: The Hidden Regulators in Cancer Progression

Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that do not code for proteins but play critical roles in gene regulation. In cancer, lncRNAs influence chromatin modification, transcription, and post-transcriptional processes. In PDAC, dysregulated lncRNAs contribute to proliferation, invasion, metastasis, and drug resistance by acting as sponges for microRNAs (miRNAs) or modulating signaling pathways.

Recent reviews highlight how lncRNAs like HOTAIR and MALAT1 promote epithelial-to-mesenchymal transition (EMT) and stemness in PDAC cells. These molecules represent untapped therapeutic targets, as silencing them can restore sensitivity to chemotherapies.

Discovery of SNHG10: A Key lncRNA in PDAC

A groundbreaking study published on March 31, 2026, in Cell Death Discovery identifies small nucleolar RNA host gene 10 (SNHG10) as a pivotal driver in PDAC. Led by researchers at Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh in Noida, India, the team analyzed The Cancer Genome Atlas (TCGA) data from 179 PDAC tumors and 171 normal pancreatic tissues. SNHG10 expression was significantly elevated in tumors, correlating with advanced clinical stages.

Further validation in PDAC cell lines confirmed overexpression compared to normal pancreatic cells. This work positions Amity University as a leader in molecular oncology research, bridging basic science with clinical implications.Read the full study here.

🧬 SNHG10's Role in Tumor Growth and Invasion

Silencing SNHG10 using targeted RNA interference dramatically curtailed PDAC cell behaviors. Key effects included:

• Reduced proliferation and clonogenic survival.
• Inhibited migration and invasion.
• Suppressed EMT markers like vimentin and N-cadherin, while boosting E-cadherin.
• Induced G2/M cell cycle arrest via upregulated p21 and downregulated cyclins (B1, D1), CDKs (4,6), and aurora kinases (A,B).
• Triggered apoptosis through reduced survivin.

In xenograft mouse models, SNHG10-depleted tumors were markedly smaller, demonstrating in vivo relevance.

Deciphering the Molecular Mechanism: Dual Axes of Action

SNHG10 exerts its oncogenic effects through two interconnected pathways:

1. miR-150-5p/VEGF-A Axis: SNHG10 sponges miR-150-5p, a tumor-suppressive microRNA. This derepresses vascular endothelial growth factor A (VEGF-A), promoting angiogenesis and tumor vascularization. RNA immunoprecipitation (RIP) and qRT-PCR confirmed the SNHG10/miR-150-5p/VEGF-A ternary complex. Restoring miR-150-5p rescued VEGF-A even under SNHG10 knockdown.
2. EGFR/AKT/ERK/mTOR Pathway: SNHG10 activates epidermal growth factor receptor (EGFR) phosphorylation, igniting downstream AKT, ERK1/2, mTOR, and c-MET signaling. These pathways fuel survival, proliferation, and resistance signals.

This step-by-step dysregulation creates a pro-tumorigenic feedback loop.

Gemcitabine Resistance: SNHG10 as the Hidden Culprit

Gemcitabine resistance plagues PDAC therapy, involving efflux pumps, DNA repair, and microenvironmental factors. The study generated gemcitabine-resistant PDAC cells, where SNHG10 was upregulated. Knocking down SNHG10 restored sensitivity, reducing IC50 values and enhancing cell death. This links SNHG10 directly to clinical resistance, as pathway inhibition mirrored effects.

Experimental Rigor: From Bench to Preclinical Models

The multidisciplinary team employed TCGA bioinformatics, qRT-PCR, Western blots, RIP assays, EdU incorporation, wound healing, Transwell invasion, flow cytometry for apoptosis/cell cycle, and orthotopic xenografts. Collaborators from Regional Centre for Biotechnology (India), National University of Singapore, and NIPER Ahmedabad enriched the study. All animal work followed ethical guidelines (Approval RCB/IAEC/2022/145).

Clinical Implications and Prognostic Value

High SNHG10 levels correlate with advanced PDAC stages, suggesting biomarker potential for risk stratification. In patient cohorts, elevated expression predicts poorer survival. Targeting SNHG10 could sensitize tumors to gemcitabine, potentially improving outcomes for the 80 percent of patients ineligible for surgery.Pancreatic Cancer Action Network insights.

Future Therapeutic Strategies

Antisense oligonucleotides (ASOs) or CRISPR-based editing could silence SNHG10. Combining with gemcitabine or VEGF inhibitors (e.g., bevacizumab) holds promise. Ongoing trials in lncRNA therapeutics for other cancers pave the way. Amity University's work highlights India's growing role in global cancer research.

Photo by Terry Vlisidis on Unsplash

Broader Landscape: lncRNAs Beyond SNHG10

Other lncRNAs like HOTTIP and ZFAS1 similarly drive PDAC via ceRNA networks. Reviews emphasize their diagnostic and prognostic utility, with liquid biopsies detecting circulating lncRNAs. Integrating multi-omics could personalize therapy.